Showing 261-270 of 297 results for "".
Safe, Effective Treatments for Hair Loss
https://practicaldermatology.com/topics/hair-nails/safe-effective-treatments-for-hair-loss/26951/Safe, Effective Treatments for Hair LossWhat Dermatologists Should Know About Advocacy
https://practicaldermatology.com/topics/practice-management/what-dermatologists-should-know-about-advocacy/23678/The specialty needs advocacy. Here’s why and how to get involved.Overcoming Adherence Challenges in the Management of Teen Acne
https://practicaldermatology.com/topics/practice-management/overcoming-adherence-challenges-in-the-management-of-teen-acne/20591/Adherence to acne treatment regimens is notoriously low among pre-teens and adolescents. Here's how to change that.As New Jersey Goes, So Goes the Nation?
https://practicaldermatology.com/topics/practice-management/as-new-jersey-goes-so-goes-the-nation/20515/New Jersey's doctor gift ban may be the tip of the iceberg.Our Competition and Our Physical Plant
https://practicaldermatology.com/topics/practice-management/our-competition-and-our-physical-plant/23161/- Dermira Prices Initial Public Offeringhttps://practicaldermatology.com/news/20141003-dermira_prices_initial_public_offering/2459096/Dermira will price its initial public offering of 7,812,500 shares of common stock at a price to the public of 16 dollars per share. The shares are expected to begin trading on The NASDAQ Global Select Market on October 3, 2014 under the symbol DERM.Citigroup and Leerink Partners are acti
- Valeant's Patient Access And Pricing Committee Announces Pricing For SILIQ as Lowest Priced Injectable Biologic For Psoriasishttps://practicaldermatology.com/news/valeants-patient-access-and-pricing-committee-announces-pricing-for-siliq-as-lowest-priced-injectable-biologic-for-psoriasis/2458215/Following the evaluation and approval of its Patient Access and Pricing Committee (PAPC), Valeant Pharmaceuticals International, Inc. has decided to list SILIQ (brodalumab) injection at $3,500 per month, which is the lowest injectable biologic psoriasis treatment cur
- Aclaris Announces Pricing of Initial Public Offeringhttps://practicaldermatology.com/news/aclaris-announces-pricing-of-initial-public-offering/2458854/Aclaris Therapeutics, Inc. announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $11.00 per share. The shares, approved for listing on The NASDAQ Global Select Market, will be traded under the ticker symbol ACRS. All of the common
- Revance Therapeutics Announces Pricing of Initial Public Offeringhttps://practicaldermatology.com/news/20140207-revance_therapeutics_announces_pricing_of_initial_public_offering/2459346/Revance Therapeutics, Inc., a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, announced the pricing of its initial public offering of 6,000,000 shares of its common stock at a public offering price of $16.00 per share, befo
- Cynthia Nixon Partners with Galderma and the NRS to Raise Awareness for Rosaceahttps://practicaldermatology.com/news/20130314-cynthia_nixon_partners_with_galderma_and_the_nrs_to_raise_awareness_for_rosacea/2459591/Actress Cynthia Nixon recently joined with dermatologists Rick Fried, MD and Flor Mayoral, MD and a panel of other experts at the "Face to Face with Rosacea: Empowering Professionals and Patients" educational event at the AAD Meeting in Miami. Sponsored by Galderma in conjunction with the National R